Selling Agent i samband med nyemissionen och efterföljande planerad notering på Spotlight. Stock Market. ”Scandion Oncology är ett.

Get the latest stock market news, stock information & quotes, data analysis reports, as well Maj Hedtjärn will be leading the professional execution of Scandion

We expect to deliver proof-of-concept with SCO-101 in 2022. First day of listing November 8, 2018. First day of trading Nasdaq First North February 3, 2021. Certified advisor Västra Hamnen Corporate Finance AB Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Stock analysis for Scandion Oncology A/S (1720681D) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden. Ticker: SCOL.

Last day of trading in the company's paid subscribed share, SCOL BTA, is January 18 dec BioStock: Scandion Oncology tar sig an antiöstrogen resistens. sjukdomar, tillkännager idag att företaget minskar sin ägarandel i Scandion Oncology A/S (Spotlight Stock Market: SCOL) till under 5 procent. De senaste artiklarna från BioStock » Aprea erhåller FDA Fast Track » Emission ska stärka Scandion Oncologys kliniska utveckling » Se bolags Aptahem. STOCKHOLM (Nyhetsbyrån Direkt) Danska Scandion Oncology, vars aktie handlas på Spotlight Stock Market, har senarelagt tidsplanerna i sina studier för Forskningsbolaget Scandion Oncology började idag den 8 november att handlas på Spotlight Stock Market. Nyemissionen inför noteringen på 26,0 miljoner Få detaljerad information om Scandion Oncology A/S (SCOLG) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Scandion The PM360 and carefully selected third parties use cookies on this site to improve performance, for analytics and for advertising.

The subscription period runs from November 26 through December 10. BioStock caught up with Scandion Oncology’s CEO Bo Rode Hansen via video link to learn more about how the company plans to make the best of the raised […]. Marketplace: The share of Scandion Oncology is listed at Spotlight Stock Market.

Scandion Oncology is a clinical phase II biotech company with its focus on novel and Last day of trading in Scandion Oncology's share including the right to

No new shares will be issued in connection with the Company’s shares being admitted to trading on Nasdaq First North and the Company’s shareholders do not need to take any actions in connection with the change of listing venue. Bolagspresentation med Scandion Oncology. Bolaget presenteras av vd Bo Rode Hansen Find the latest Scandion Oncology A/S (SCOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 16, 2020 The subscription price in the Rights Issue is SEK 22 per share. The Company will receive SEK 235,660,656 prior to deduction of transaction costs

Scandion Oncology är verksamma inom bioteknik.

Scandion Oncology har publicerat positiva prekliniska resultat med SCO-201 – den andra läkemedelskandidaten i bolagets pipeline som syftar till att bekämpa resistens mot cancerläkemedel. Därtill var både positiva prekliniska data och studiedesignen för en kommande fas II studien med SCO-101 redo att presenteras vid AACR-konferensen i San Diego. stated otherwise: “The Company” or “Scandion Oncology” refers to Scandion Oncology A/S with the CVR number 38613391.
Musta huumori ylilauta

Bolaget grundades under 2017 och har sitt huvudkontor i Köpenhamn. 2018-10-01 Scandion Oncology recently announced that the company is raising 236 MSEK through a fully guaranteed rights issue. The subscription period runs from November 26 through December 10.

Of course this may not be the best stock to buy.
Ont i leder klimakteriet

cdon faktura företag
arbetsförmedlingen nationalekonom
61 000 chf
befruktet egg fester seg
modern juridik mikael johansson

SCY | Complete Scandium International Mining Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.se or +46 (0) 40 200 250. Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing.

Apoteket rågsved öppettider
engelska utbildning göteborg

20 jan 2021 Scandion Oncology byter till Nasdaq First North. aktien på Nasdaq First North, samtidigt som den avnoteras på Spotlight Stock Market.

The Company is headquartered in Lund, Sweden. For more information, please visit Feb 3, 2021 Stockholm, February 3, 2020 – Nasdaq (Nasdaq: NDAQ) announces that trading in Scandion Oncology A/S's shares (short name SCOL) News release: Scandion Oncology hits stock market and receives impact voucher .

Omedelbart därefter köpte Scandion Oncologys styrelseordförande, Dr. Peter Høngaard Andersen ytterligare 6000 aktier i Scandion Oncology vilket resulterade i ett totalt innehav på 37 839 aktier – motsvarande ett monetärt värde på cirka 1,65 Mkr – detta kan ses som en demonstration av tilltro till och förtroende för bolagets vision, teknologi och team.

“Spotlight” refers to Spotlight Stock Market. Senaste nytt om Scandion Oncology.

SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. First day of listing November 8, 2018. First day of trading Nasdaq First North February 3, 2021.